New Data from PURPOSE Trials Further Demonstrate that Lenacapavir (Yeztugo®) was Effective and Well Tolerated Across a Broad Range of Populations, Including ...

SOUTH SAN FRANCISCO, CA, USA I July 14, 2025 I Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human ...

First patient dosing in Company’s Phase 2b trial marks pivotal milestone in phage therapy development program targeting antibiotic-resistant lung infections ...

DALLAS, TX, USA I July 14, 2025 I Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel gene-agnostic ...

LOS ANGELES, CA, USA I July 14, 2025 I Turn Therapeutics today announced the initiation of a randomized, double-blind, vehicle-controlled clinical trial ...

In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally ...

TSLP inhibitor Tezspire clinically has validated Thymic Stromal LymphoPoietin (TSLP) as a valid target for treatment of inflammatory diseases by its approval in late 2021 in the US and in 2022 in ...